HCW Biologics Announces Pricing of $1.5 Million Private Placement
HCW Biologics Inc HCWB
$1.93
▼ -3.02%
($-0.06)
🎈 Low Float
🎢 High Beta
Open
$1.88
Prev Close
$1.99
Day Range
$1.81 – $2.00
52W Range
$1.50 – $29.28
Market Cap
$4.45M
Beta
2.29
EPS (TTM)
$-10.91
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-07-20 |
| Shares Out. | 1,600,000 |
| Website | hcwbiologics.com/ ↗ |
| Phone | 18009279800 |
| Employees | 35 |
| Revenue | $135,568 |
| Gross Profit | -$93,887 |
| Net Income | -$5.2M |
| Free Cash Flow | -$12.1M |
| Total Assets | $26.8M |
| Total Liabilities | $19.3M |
| Equity | $7.4M |
About HCW Biologics Inc
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
HCW Biologics Inc is a publicly traded company under the ticker symbol HCWB on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-09-01)